<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Acta Naturae</journal-id><journal-title-group><journal-title xml:lang="en">Acta Naturae</journal-title><trans-title-group xml:lang="ru"><trans-title>Acta Naturae</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-8251</issn><publisher><publisher-name xml:lang="en">Acta Naturae Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10398</article-id><article-id pub-id-type="doi">10.32607/20758251-2017-9-1-38-44</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Research Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Экспериментальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro</article-title><trans-title-group xml:lang="ru"><trans-title>Сфероиды HER2-положительной аденокарциномы молочной железы человека как модель для тестирования противоопухолевых иммунотоксинов</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Balalaeva</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Балалаева</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>irin-b@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sokolova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Соколова</surname><given-names>E. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>irin-b@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Puzhikhina</surname><given-names>A. D.</given-names></name><name xml:lang="ru"><surname>Пужихина</surname><given-names>A. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>irin-b@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Brilkina</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Брилкина</surname><given-names>A. A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>irin-b@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Deyev</surname><given-names>S. M.</given-names></name><name xml:lang="ru"><surname>Деев</surname><given-names>С. M.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>irin-b@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Lobachevsky State University of Nizhny Novgorod</institution></aff><aff><institution xml:lang="ru">Нижегородский государственный университет им. Н.И. Лобачевского</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">National Research Tomsk Polytechnic University</institution></aff><aff><institution xml:lang="ru">Национальный исследовательский Томский политехнический университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-03-15" publication-format="electronic"><day>15</day><month>03</month><year>2017</year></pub-date><volume>9</volume><issue>1</issue><issue-title xml:lang="en">VOL 9, NO1 (2017)</issue-title><issue-title xml:lang="ru">ТОМ 9, №1 (2017)</issue-title><fpage>38</fpage><lpage>44</lpage><history><date date-type="received" iso-8601-date="2020-01-17"><day>17</day><month>01</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Balalaeva I.V., Sokolova E.A., Puzhikhina A.D., Brilkina A.A., Deyev S.M.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Балалаева И.В., Соколова E.A., Пужихина A.Д., Брилкина A.A., Деев С.M.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Balalaeva I.V., Sokolova E.A., Puzhikhina A.D., Brilkina A.A., Deyev S.M.</copyright-holder><copyright-holder xml:lang="ru">Балалаева И.В., Соколова E.A., Пужихина A.Д., Брилкина A.A., Деев С.M.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://actanaturae.ru/2075-8251/article/view/10398">https://actanaturae.ru/2075-8251/article/view/10398</self-uri><abstract xml:lang="en"><p>Tumor response to therapeutic treatment is largely determined by its heterogeneity and the presence of intercellular junctions, hindering the penetration of large molecules deep into the three-dimensional structure of the tumor. In that context, 3D in vitro tumor models such as cancer cell spheroids are becoming increasingly popular. We obtained spheroids of human breast adenocarcinoma SKBR-3 overexpressing the HER2 cancer marker. The toxicity of HER2-targeted immunotoxin 4D5scFv-PE40 against spheroids was shown to be several orders of magnitude lower compared to a monolayer cell culture. The significant difference in the severity of the immunotoxin effect can be explained by the fact that it ineffectively penetrates the spheroid and predominantly influences the cells of the outer layers. The resulting tumor spheroid model can be used in development of drugs for targeted therapy as well as to study ways to improve the efficiency of anticancer agents by targeting cell-cell contacts.</p></abstract><trans-abstract xml:lang="ru"><p>Ответ опухоли на терапевтическое воздействие во многом определяется ее гетерогенностью и межклеточными контактами, которые затрудняют проникновение крупных молекул в глубь трехмерной структуры. В связи с этим все большее распространение получают трехмерные модели опухолей in vitro, такие, как сфероиды опухолевых клеток. Нами получены сфероиды аденокарциномы молочной железы человека SKBR-3, сверхэкспрессирующей онкомаркер HER2. Показано, что токсичность HER2-специфичного противоопухолевого иммунотоксина 4D5scFv-PE40 в отношении сфероидов на несколько порядков ниже, чем для монослойной культуры той же линии клеток. Существенную разницу в выраженности действия иммунотоксина можно объяснить его неэффективным проникновением в глубь сфероида и воздействием только на клетки внешних слоев. Полученная модель опухолевого сфероида может быть использована как при разработке препаратов для таргетной терапии, так и при исследовании путей повышения эффективности противоопухолевых агентов за счет направленного воздействия на межклеточные контакты.</p></trans-abstract><kwd-group xml:lang="en"><kwd>4D5scFv-PE40 immunotoxin</kwd><kwd>cancer marker HER2</kwd><kwd>drug penetration into tumor</kwd><kwd>spheroids</kwd><kwd>targeted therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>иммунотоксин 4D5scFv-PE40</kwd><kwd>онкомаркер HER2/neu</kwd><kwd>сфероиды</kwd><kwd>проникновение терапевтического агента в опухоль</kwd><kwd>таргетная терапия</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This work was supported by the Ministry of Education and Science of the Russian Federation (agreement No. 14.578.21.0051, unique identifier RFMEFI57814X0051).</funding-statement><funding-statement xml:lang="ru">Работа выполнена при поддержке Минобрнауки РФ (соглашение № 14.578.21.0051, уникальный идентификатор RFMEFI57814X0051).</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>[1] Minchinton A.I., Tannock I.F. // Nat. Rev. Cancer. 2006, V.6, №8, P.583-592</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>[2] Antoni D., Burckel H., Josset E., Noel G. // Int. J. Mol. Sci. 2015, V.16, №3, P.5517-5527</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>[3] Weiswald L.B., Bellet D., Dangles-Marie V. // Neoplasia. 2015, V.17, №1, P.1-15</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>[4] Deyev S.M., Lebedenko E.N., Petrovskaya L.E., Dolgikh D.A., Gabibov A.G., Kirpichnikov M.P. // Russ. Chem. Rev. 2015, V.84, P.1-26</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>[5] Hynes N.E., Gerber H.A., Saurer S., Groner B. // J. Cell Biochem. 1989, V.39, №2, P.167-173</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>[6] Sokolova E.A., Zdobnova T.A., Stremovskiy O.A., Balalaeva I.V., Deyev S.M. // Biochemistry (Mosc.). 2014, V.79, №12, P.1376-1381</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>[7] Mosmann T. // J. Immunol. Meth. 1983, V.65, №1-2, P.55-63</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>[8] Glinsky V.V., Huflejt M.E., Glinsky G.V., Deutscher S.L., Quinn T.P. // Cancer Research 2000, V.60, №10, P.2584-2588</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>[9] Ivascu A., Kubbies M. // Int. J. Oncol. 2007, V.31, №6, P.1403-1413</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>[10] Froehlich K., Haeger J.D., Heger J., Pastuschek J., Photini S.M., Yan Y., Lupp A., Pfarrer C., Mrowka R., Schleussner E., Markert U.R., Schmidt A. // J. Mammary Gland Biol. Neoplasia. 2016, V.21, №3-4, P.89-98</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>[11] Akasov R., Haq S., Haxho F., Samuel V., Burov S.V., Markvicheva E., Neufeld R.J., Szewczuk M.R. // Oncotarget. 2016, V.7, №40, P.66119-66134</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>[12] Debnath J., Brugge J.S. // Nat. Rev. Cancer. 2005, V.5, №9, P.675-688</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>[13] Hjelstuen M.H., Rasch-Halvorsen K., Brekken C., Bruland O. // Acta Oncol. 1996, V.35, №3, P.273-279</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>[14] Lin R.Z., Chang H.Y. // Biotechnol. J. 2008, V.3, №9-10, P.1172-1184</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>[15] Polanovski O.L., Lebedenko E.N., Deyev S.M. // Biochemistry. 2012, V.77, №3, P.227-245</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>[16] Harari D., Yarden Y. // Oncogene. 2000, V.19, №53, P.6102-6114</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>[17] Yan M., Parker B.A., Schwab R., Kurzrock R. // Cancer Treat Rev. 2014, V.40, №6, P.770-780</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>[18] Kreitman R.J. // Aaps J. 2006, V.8, №3, P.E532-551</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>[19] Mueller S., Cadenas E., Schonthal A.H. // Cancer Research 2000, V.60, №1, P.156-163</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>[20] Xiang X., Phung Y., Feng M., Nagashima K., Zhang J., Broaddus V.C., Hassan R., Fitzgerald D., Ho M. // PLoS One. 2011, V.6, №1, e14640</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>[21] Weldon J.E., Pastan I. // FEBS J. 2011, V.278, №23, P.4683-4700</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>[22] Sokolova E.A., Stremovskiy O.A., Zdobnova T.A., Balalaeva I.V., Deyev S.M. // Acta Naturae. 2015, V.7, №4, P.93-96</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>[23] Niero E.L., Rocha-Sales B., Lauand C., Cortez B.A., de Souza M.M., Rezende-Teixeira P., Urabayashi M.S., Martens A.A., Neves J.H., Machado-Santelli G.M. // J. Exp. Clin. Cancer Res. 2014, V.33, P.37</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>[24] Fong E.L., Harrington D.A., Farach-Carson M.C., Yu H. // Biomaterials. 2016, V.108, P.197-213</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>[25] Zdobnova T., Sokolova E., Stremovskiy O., Karpenko D., Telford W., Turchin I., Balalaeva I., Deyev S. // Oncotarget. 2015, V.6, №31, P.30919-30928</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>[26] Weldon J.E., Xiang L., Zhang J., Beers R., Walker D.A., Onda M., Hassan R., Pastan I. // Mol. Cancer Ther. 2013, V.12, №1, P.48-57</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>[27] Zielinski R., Lyakhov I., Hassan M., Kuban M., Shafer-Weaver K., Gandjbakhche A., Capala J. // Clin. Cancer Res. 2011, V.17, №15, P.5071-5081</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>[28] Cao Y., Marks J.W., Liu Z., Cheung L.H., Hittelman W.N., Rosenblum M.G. // Oncogene. 2014, V.33, №4, P.429-439</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>[29] Sutherland R., Buchegger F., Schreyer M., Vacca A., Mach J.P. // Cancer Research 1987, V.47, №6, P.1627-1633</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>[30] Choi I.K., Strauss R., Richter M., Yun C.O., Lieber A. // Front. Oncol. 2013, V.3, P.193</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>[31] Beyer I., van Rensburg R., Lieber A. // Tissue Barriers. 2013, V.1, №1, e23647</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>[32] Beyer I., van Rensburg R., Strauss R., Li Z., Wang H., Persson J., Yumul R., Feng Q., Song H., Bartek J., Fender P., Lieber A. // Cancer Research 2011, V.71, №22, P.7080-7090</mixed-citation></ref></ref-list></back></article>
